Zeteo Biomedical has joined forces with Iowa State University’s (ISU) Nanovaccine Institute to research a nasal COVID-19 vaccine.

The Austin, Tex., company will contribute its ZEOx2 nasal delivery technology, including devices that support powder and reconstituted powder-to-liquid vaccine formulations that can be administered by either healthcare providers or patients. The company said the nasal delivery devices are commercially scalable to deliver millions of vaccine doses per day.

ISU’s vaccine is “intended to address some of the limitations of the vaccines currently in development by targeting room temperature storage and single-dose nasal self-administration as key capabilities,” Zeteo said.